RPL22

Large ribosomal subunit protein eL22 · P35268 · RPL22 on Sugi Atlas →

3,676 patent compounds predicted against RPL22, 1,926 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
SCHEMBL5500526	0.41	4/20
SCHEMBL5500532	0.41	4/20
SCHEMBL5503310	0.41	4/20
SCHEMBL11844361	0.35	4/20
SCHEMBL2000440	0.39	3/20
SCHEMBL8219903	0.36	3/20
SCHEMBL11627320	0.34	3/20
SCHEMBL10271044	0.55	2/20
SCHEMBL6394396	0.47	2/20
N-Methylpiperidine (SCHEMBL11205373)	0.42	2/20
Bicarbonate (SCHEMBL9058396)	0.42	2/20
SCHEMBL4960293	0.41	2/20
SCHEMBL4961968	0.40	2/20
SCHEMBL6686992	0.40	2/20
SCHEMBL9429122	0.38	2/20
Chloramphenicol (SCHEMBL10796001)	1.00	1/20
Geneticin (SCHEMBL15596)	0.93	1/20
Geneticin (SCHEMBL5006573)	0.93	1/20
Geneticin (SCHEMBL9920496)	0.93	1/20
Chloramphenicol (SCHEMBL16111)	0.90	1/20

Clinical trials — most relevant to RPL22 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
COMPARING TWO PROTOCOLS FOR FINAL OOCYTE MATURATION IN POOR RESPONDERS UNDERGOING GnRH-ANTAGONIST ICSI CYCLES	PHASE3	UNKNOWN
Everolimus for Children With Recurrent or Progressive Ependymoma	PHASE2	COMPLETED
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients	PHASE2	COMPLETED
Cixutumumab and Temsirolimus in Treating Patients With Metastatic Prostate Cancer	PHASE1/PHASE2	COMPLETED
Gemcitabine Hydrochloride and Tanespimycin in Treating Patients With Recurrent Advanced Ovarian Epithelial or Peritoneal Cavity Cancer	PHASE2	COMPLETED
Study of Decitabine in Combination With Sequential Rapamycin or Ribavirin in High Risk AML Patients	PHASE1/PHASE2	COMPLETED
Targeting Endoplasmic Reticulum Stress in Human Hypertension	PHASE1/PHASE2	RECRUITING
Temsirolimus and Sorafenib in Advanced Hepatocellular Carcinoma	PHASE1	COMPLETED
Assessing the Safety, Tolerability, and Efficacy of APR-2020 in Pediatric and Adolescent Subjects With RPS19 Deficient Diamond-Blackfan Anemia	PHASE1	RECRUITING
Safety and Pharmacology of SNX-5422 Plus Carboplatin and Paclitaxel in Subjects With Solid Tumors	PHASE1	COMPLETED
17-N-Allylamino-17-Demethoxygeldanamycin in Treating Patients With Solid Tumors That Cannot Be Removed By Surgery	PHASE1	COMPLETED
Study of Oral CNF2024 (BIIB021) in Advanced Solid Tumors	PHASE1	COMPLETED
Micro Ribosomal Nucleic Acid 155 in Non Hodgkin Lymphoma	nan	COMPLETED
Modulation of Steroid Immunosuppression by Alveolar Efferocytosis	nan	COMPLETED
Positional Cloning of the Gene(s) Responsible for Alagille Syndrome	nan	COMPLETED
Endolymphatic Sac Tumors in a Population of Patients With Von Hippel-Lindau Disease:The Natural History and Pathobiology, and a Prospective Non-Randomized Clinical Trial of Hearing Preservation Surgery in Patients With Early Stage Endolymphatic Sac Tumors	nan	COMPLETED
miR-155 Expression in Episodic and Chronic Migraine	nan	UNKNOWN
Identifying Genes and Mutations Underlying Retinitis Pigmentosa and Allied Diseases	nan	UNKNOWN
Genetic Variation in TRAF3IP2 (rs13190932)	nan	RECRUITING
MiRNA223 and HMGB1 as Apredictos for Drug Resistant Epilepsy	nan	UNKNOWN
Somatosensory Modulation of Salivary Gene Expression and Oral Feeding in Preterm Infants	nan	COMPLETED
MEHMO Natural History and Biomarkers	nan	RECRUITING
Steroid Treatment of Idiopathic Nephrotic Syndrome	nan	COMPLETED
Transcripts with Retained H/ACA Box SnoRNA Sequences As Biomarkers for Estrogen Dependence in Lum-B Breast Carcinomas	nan	ACTIVE_NOT_RECRUITING
Chronic Cough and CANVAS (Cerebellar Ataxia With Neuropathy and Bilateral Vestibular Areflexia Syndrome)	nan	COMPLETED
Role of Sorcin and Annexin A3 in Breast Cancer Patients	nan	UNKNOWN
Gene Expression, Metabolomic, Microbiome, and Calcium Metabolism in Response to Varied Vitamin D Dosages	nan	COMPLETED
Impact of Mutations in Aminoacyl tRNA Synthetases on Protein Translation and Cellular Stress	nan	WITHDRAWN
Detection of MicroRNA-25 in the Diagnosis of Pancreatic Cancer	nan	UNKNOWN
Role of Piwi-protein Interacting RNA, miRNA-194 and Amino Acids in Patients With Prostate Cancer	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a RPL22 binder may also engage these)

Protein	Name	Similarity
Q4R5I3	—	1.000	Q4R5I3 →
P67985	—	0.999	P67985 →
P67984	—	0.997	P67984 →
Q98TF8	—	0.994	Q98TF8 →
P47198	—	0.989	P47198 →
G1TSG1	—	0.986	G1TSG1 →
Q90YU6	—	0.980	Q90YU6 →
Q9D7S7	—	0.970	Q9D7S7 →
Q6P5R6	—	0.966	Q6P5R6 →
A4FUH0	—	0.961	A4FUH0 →
P50886	—	0.959	P50886 →
Q28IL6	—	0.954	Q28IL6 →
P62084	—	0.945	P62084 →
P02362	—	0.945	P02362 →
A6H769	—	0.943	A6H769 →
G1SVB0	—	0.943	G1SVB0 →
P50894	—	0.941	P50894 →
Q90YR7	—	0.940	Q90YR7 →
G1TU13	—	0.940	G1TU13 →
P04644	—	0.940	P04644 →
Q90YQ6	—	0.939	Q90YQ6 →
P62083	—	0.939	P62083 →
Q5RT64	—	0.939	Q5RT64 →
A5PK63	—	0.939	A5PK63 →
P63275	—	0.939	P63275 →
P63274	—	0.939	P63274 →
Q6QAP7	—	0.939	Q6QAP7 →
P63276	—	0.939	P63276 →
P08636	—	0.938	P08636 →
Q7ZUB2	—	0.938	Q7ZUB2 →